ArticleOncology letters2017
Cytotoxic effects of zoledronic acid-loaded hydroxyapatite and bone cement in malignant tumors.
Article in Oncology letters, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 26 citations in OpenAlex.
- Review
- A Toolbox of Bone Consolidation for the Interventional Radiologist.Cardiovascular and interventional radiology · 2023Review
- Functionalization of Octacalcium Phosphate Bone Graft with Cisplatin and Zoledronic Acid: Physicochemical and Bioactive Properties.International journal of molecular sciences · 2023Article
- In vivo antitumor efficacy of 17-AAG loaded PMMA in a human multiple myeloma xenograft mouse model.Clinical and experimental medicine · 2023Article
- Bisphosphonate-loaded bone cement: Background, clinical indications and future perspectives.Journal of musculoskeletal & neuronal interactions · 2022Review
- Dual-functional porous and cisplatin-loaded polymethylmethacrylate cement for reconstruction of load-bearing bone defect kills bone tumor cells.Bioactive materials · 2022Article
- The optimized drug delivery systems of treating cancer bone metastatic osteolysis with nanomaterials.Drug delivery · 2021Review
- Release characteristics of enoxaparin sodium-loaded polymethylmethacrylate bone cement.Journal of orthopaedic surgery and research · 2021Article
- Bone cement as a local chemotherapeutic drug delivery carrier in orthopedic oncology: A review.Journal of bone oncology · 2021Review
- Anti-Tumor Effects of Low Dose Zoledronate on Lung Cancer-Induced Spine Metastasis.Journal of clinical medicine · 2019Article
- Advances in personalized treatment of metastatic spine disease.Annals of translational medicine · 2019Review
- Low-dose zoledronate for the treatment of bone metastasis secondary to prostate cancer.Cancer cell international · 2019Article
- Role of Bisphosphonates as Adjuvants of Surgery in Giant Cell Tumor of Spine.International journal of spine surgery · 2018Article
- Anti-tumour effects of polysaccharide extracted fromExperimental and therapeutic medicine · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metastatic and primary bone tumors are malignant tumors affecting the skeleton. Although the prognosis of patients with these tumors has improved with the development of effective chemotherapy, the challenges of local recurrence, subsequent osteolysis, degradation of bone strength and unresectable tumors persist. Local control of these tumors is therefore a key strategy to address these limitations. The third-generation bisphosphonate (BP), zoledronic acid (ZOL), has been demonstrated to reduce osteoclasts and exhibited potent antitumor effects in a number of malignancies. Hydroxyapatite (HA) and polymethyl methacrylate (PMMA) bone cement are used in orthopedic surgery as bone graft substitutes, for implant arthroplasty and bone strengthening, and as a sustained-release system for drugs such as antibiotics. At present, the antitumor effects of ZOL-loaded HA
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.